Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 25;11(17):4980.
doi: 10.3390/jcm11174980.

Predictors of Long COVID in Patients without Comorbidities: Data from the Polish Long-COVID Cardiovascular (PoLoCOV-CVD) Study

Affiliations

Predictors of Long COVID in Patients without Comorbidities: Data from the Polish Long-COVID Cardiovascular (PoLoCOV-CVD) Study

Michał Chudzik et al. J Clin Med. .

Abstract

Background: The SARS-CoV-2 pandemic has become an enormous worldwide challenge over the last two years. However, little is still known about the risk of Long COVID (LC) in patients without comorbidities. Thus, we aimed to assess the predictors of LC in patients without comorbidities. Methods: Patients’ information, the course of the disease with symptoms, and post-COVID-19 complaints were collected within 4−12 weeks after COVID-19 recovery. Next, the patients were followed for at least 3 months. ECG, 24-h ECG monitoring, 24-h blood pressure (BP) monitoring, echocardiography, and selected biochemical tests were performed. LC was recognized based on the WHO definition. Results: We identified 701 consecutive patients, 488 of whom completed a 3-month follow-up (63% women). Comparisons were made between the LC group (n = 218) and patients without any symptoms after SARS-CoV-2 recovery (non-LC group) (n = 270). Patients with a severe course of acute-phase COVID-19 developed LC complications more often (34% vs. 19%, p < 0.0001). The persistent symptoms were observed in 45% of LC patients. The LC group also had significantly more symptoms during the acute phase of COVID-19, and they suffered significantly more often from dyspnoea (48 vs. 33%), fatigue (72 vs. 63%), chest pain (50 vs. 36%), leg muscle pain (41 vs. 32%), headache (66 vs. 52%), arthralgia (44 vs. 25%), and chills (34 vs. 25%). In LC patients, significant differences regarding sex and body mass index were observed—woman: 69% vs. 56% (p = 0.003), and BMI: 28 [24−31] vs. 26 kg/m2 [23−30] (p < 0.001), respectively. The number of symptoms in the acute phase was significantly greater in the LC group than in the control group (5 [2−8] vs. 2 [1−5], p = 0.0001). The LC group also had a higher 24-h heart rate (77 [72−83] vs. 75 [70−81], p = 0.021) at admission to the outpatient clinic. Multivariate regression analysis showed that LC patients had a higher BMI (odds ratio (OR): 1.06, 95% confidence intervals [CI]: 1.02−1.10, p = 0.007), almost twice as often had a severe course of COVID-19 (OR: 1.74, CI: 1.07−2.81, p = 0.025), and presented with joint pain in the acute phase (OR: 1.90, CI: 1.23−2.95, p = 0.004). Conclusions: A severe course of COVID-19, BMI, and arthralgia are independently associated with the risk of Long COVID in healthy individuals.

Keywords: COVID complications; COVID-19; Long COVID; chronic fatigue syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
ROC analysis for the prediction of LC development by BMI. AUC = 0.541 (0.492–0.589), p = 0.099.

References

    1. World Health Organization (WHO) Living Guidance for Clinical Management of COVID-19 2021. World Health Organization (WHO); Geneva, Switzerland: 2021. [(accessed on 23 November 2021)]. Available online: www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2.
    1. Antoniou K., Vasarmidi E., Russell A.M., Andrejak C., Crestani B., Delcroix M., Dinh-Xuan A.T., Poletti V., Sverzellati N., Vitacca M., et al. European Respiratory Society Statement on Long COVID-19 Follow-Up. Eur. Respir. J. 2022;60:2102174. doi: 10.1183/13993003.02174-2021. - DOI - PMC - PubMed
    1. Ganesh R., Grach S.L., Ghosh A.K., Bierle D.M., Salonen B.R., Collins N.M., Joshi A.Y., Boeder N.D., Jr., Anstine C.V., Mueller M.R., et al. The Female-Predominant Persistent Immune Dysregulation of the Post-COVID Syndrome. Mayo Clin. Proc. 2022;97:454–464. doi: 10.1016/j.mayocp.2021.11.033. - DOI - PMC - PubMed
    1. Yelin D., Moschopoulos C.D., Margalit I., Gkrania-Klotsas E., Landi F., Stahl J.P., Yahav D. ESCMID rapid guidelines for assessment and management of long COVID. Clin. Microbiol. Infect. 2022;28:955–972. doi: 10.1016/j.cmi.2022.02.018. - DOI - PMC - PubMed
    1. Peghin M., Palese A., Venturini M., De Martino M., Gerussi V., Graziano E., Bontempo G., Marrella F., Tommasini A., Fabris M., et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin. Microbiol. Infect. 2021;27:1507–1513. doi: 10.1016/j.cmi.2021.05.033. - DOI - PMC - PubMed